Impact of Triptan Insufficient Response on Medication Use, Health Care Utilization, and Costs: A Retrospective Claims Study (P1-12.002)
This study aimed to assess medication use and migraine-specific healthcare resource use (HCRU) and costs in patients with a potential insufficient response to triptans compared to patients who continue on triptans.
Authors
- Amanda Howarth
- Amit Bodhani (ORCID: https://orcid.org/0000-0001-5934-8413)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Richard A. Lipton
- Lauren E. Wilson (ORCID: https://orcid.org/0000-0002-5953-2293)
- Krutika Parikh
- Molly Duan
Institutions
- Albert Einstein College of Medicine (US)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- AbbVie (United States) (US)
- Genesis Research Institute (JP)
- AbbVie (Japan)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212193
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00